Medifast Inc (NYSE:MED – Get Free Report) Director Parsa Kiai acquired 8,886 shares of the firm’s stock in a transaction on Wednesday, November 18th. The shares were bought at an average cost of $12.16 per share, with a total value of $108,053.76. Following the completion of the acquisition, the director directly owned 721,521 shares in the company, valued at approximately $8,773,695.36. This represents a 1.25% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Parsa Kiai also recently made the following trade(s):
- On Thursday, November 19th, Parsa Kiai acquired 85,150 shares of Medifast stock. The stock was bought at an average cost of $12.05 per share, with a total value of $1,026,057.50.
- On Wednesday, November 4th, Parsa Kiai bought 661 shares of Medifast stock. The stock was bought at an average price of $13.03 per share, for a total transaction of $8,612.83.
- On Wednesday, October 28th, Parsa Kiai bought 5,557 shares of Medifast stock. The stock was bought at an average price of $12.24 per share, for a total transaction of $68,017.68.
- On Wednesday, August 26th, Parsa Kiai bought 43,150 shares of Medifast stock. The shares were bought at an average cost of $12.26 per share, for a total transaction of $529,019.00.
- On Monday, August 24th, Parsa Kiai bought 4,329 shares of Medifast stock. The shares were bought at an average cost of $12.00 per share, for a total transaction of $51,948.00.
Medifast Trading Down 1.7%
Shares of Medifast stock opened at $11.78 on Friday. The stock has a fifty day simple moving average of $12.14 and a 200 day simple moving average of $11.41. Medifast Inc has a 12-month low of $9.22 and a 12-month high of $13.63.
Medifast (NYSE:MED – Get Free Report) last released its quarterly earnings results on Monday, October 26th. The specialty retailer reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.16. Medifast had a negative return on equity of 6.90% and a negative net margin of 13.64%. The business had revenue of $72.05 million during the quarter, compared to analyst estimates of $71.30 million. On average, research analysts anticipate that Medifast Inc will post -0.52 earnings per share for the current year.
Analyst Upgrades and Downgrades
MED has been the topic of a number of recent analyst reports. Zacks Research lowered shares of Medifast from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 11th. Weiss Ratings downgraded shares of Medifast from a “sell (d)” rating to a “sell (d-)” rating in a research report on Wednesday, October 28th. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Reduce” and a consensus price target of $12.00.
Get Our Latest Research Report on Medifast
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of MED. American Century Companies Inc. increased its position in shares of Medifast by 37.7% during the 3rd quarter. American Century Companies Inc. now owns 439,221 shares of the specialty retailer’s stock valued at $5,060,000 after purchasing an additional 120,310 shares during the last quarter. Advisors Asset Management Inc. purchased a new position in shares of Medifast in the 3rd quarter worth about $106,000. Ancora Advisors LLC boosted its holdings in shares of Medifast by 411.5% in the 3rd quarter. Ancora Advisors LLC now owns 36,110 shares of the specialty retailer’s stock worth $416,000 after buying an additional 29,050 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Medifast by 46.0% in the 3rd quarter. Marshall Wace LLP now owns 352,704 shares of the specialty retailer’s stock worth $4,063,000 after buying an additional 111,055 shares during the last quarter. Finally, Commons Capital LLC boosted its holdings in shares of Medifast by 23.0% in the 3rd quarter. Commons Capital LLC now owns 184,432 shares of the specialty retailer’s stock worth $2,125,000 after buying an additional 34,516 shares during the last quarter. Hedge funds and other institutional investors own 95.51% of the company’s stock.
Medifast Company Profile
Medifast, Inc. is a health and wellness company focused on weight management and healthy living. Its products and programs are marketed primarily under the OPTAVIA brand. OPTAVIA offers structured plans that combine portion-controlled meal replacements and other nutrition products with guidance from independent coaches. The company’s approach emphasizes nutrition, behavior changes and ongoing support. Founded in 1980, Medifast serves customers primarily in the United States. Its business centers on selling products and connecting customers with coaches who provide support as they follow the company’s programs.
Featured Articles
- Five stocks we like better than Medifast
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
Receive News & Ratings for Medifast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medifast and related companies with MarketBeat.com's FREE daily email newsletter.
